deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02661035

Allo HSCT Using RIC for Hematological Diseases

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Acute Lymphocytic Leukemia Acute Myelogenous Leukemia B-Cell Lymphoma Burkitt's Lymphoma Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia Follicular Lymphoma Hematological Diseases Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle-Cell Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Syndromes Non-Hodgkin's Lymphoma Plasma Cell Leukemia Prolymphocytic Leukemia Small Lymphocytic Lymphoma
Interventions ATG Allopurinol Cyclophosphamide Fludarabine MMF Peripheral Blood Stem Cells Related or Unrelated Bone Marrow Cells TBI Tacrolimus
Updated 14 times since 2017 Last updated: Sep 19, 2023 Started: Mar 9, 2017 Primary completion: Apr 17, 2023 Completion: May 29, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02661035, this PHASE2 trial focuses on Acute Lymphocytic Leukemia and Acute Myelogenous Leukemia and remains completed. Sponsored by Masonic Cancer Center, University of Minnesota, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2018 · 14 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Oct 2020 · 12 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Dec 2022 · 18 months · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Suspended → Active Not Recruiting

  5. Dec 2022 — May 2023 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

▶ Show 9 earlier versions

  1. Jun 2021 — Dec 2022 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  3. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Oct 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  5. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  7. Apr 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations